Cover Image

Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China

Abstract Background Former single center studies indicated that HER2 assessment with two primary tumor blocks (dual block HER2 assessment) could be an efficient and practical approach to overcome the adverse impact of heterogeneity and acquire a HER2 positive rate in gastric cancer (GC). This multic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chen Xu (Author), Miaomiao Sun (Author), Mei Jin (Author), Zengshan Li (Author), Rong Qin (Author), Guoping Ren (Author), Wenyong Sun (Author), Lirong Chen (Author), Lijuan Luan (Author), Yalan Liu (Author), Dongxian Jiang (Author), Lingli Chen (Author), Rongkui Luo (Author), Yingyong Hou (Author)
Format:	Book
Published:	BMC, 2022-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer
by: Chen Xu, et al.
Published: (2017)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024)

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
by: Gokce Deniz Ardor, et al.
Published: (2023)

Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma
by: Döndü Nergiz, et al.
Published: (2022)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
by: Sun J, et al.
Published: (2022)

Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry
by: Ibrahim Al Haddabi, et al.
Published: (2014)

Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma
by: Islam Barkatullah, et al.
Published: (2021)

Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
by: Vogel Ulrich F
Published: (2010)

HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization
by: Hemlata S Shirsat, et al.
Published: (2012)

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
by: Gilhyang Kim, et al.
Published: (2016)

The History and Development of HER2 Inhibitors
by: Xiaohui Xia, et al.
Published: (2023)

Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
by: Feng Guan, et al.
Published: (2024)

The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI
by: Ismail Saygin, et al.
Published: (2022)

Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort
by: Saurav Verma, et al.
Published: (2024)

The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024)

Correlation and comparison of immunohistochemistry for HER2/neu, using the antibody SP3 and chromogenic in situ hybridization in breast carcinomas samples
by: Franciele F. Wolf, et al.
Published: (2015)

Correlation between HER2 gene amplification and protein overexpression through fluorescence in situ hybridization and immunohistochemistry in breast carcinoma patients
by: R N Makroo, et al.
Published: (2012)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022)

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
by: Luying Xu, et al.
Published: (2024)

Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by: Lu Li, et al.
Published: (2024)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
by: Bo-Wei Wang, et al.
Published: (2021)

Correlation of Serum HER-2/neu Levels with Clinico-Pathological Variables and Tissue Immunohistochemistry in Breast Carcinoma / Islam Barkatullah ... [et al.]
by: Barkatullah, Islam, et al.
Published: (2021)

Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice
by: Chiu-Hsiang Connie Liao, et al.
Published: (2024)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
by: Roberto J. Arai, et al.
Published: (2018)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
by: Antonio Fernando Leis-Filho, et al.
Published: (2021)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer
by: Xiaolin Yu, et al.
Published: (2018)

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables
by: Zaidoon A. Musa, et al.
Published: (2017)

Brenda, Her School and Her Club
by: Reed, Helen Leah, 1860?-1926; Smith, Jessie Willcox, 1863-1935 [Illustrator]

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
by: Costa R, et al.
Published: (2019)

Old Virginia and Her Neighbours, Vol. 2 (of 2)
by: Fiske, John, 1842-1901

HER2 (ERBB2) alterations in colorectal cancers
by: Nika Tavberidze, et al.
Published: (2022)

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens
by: Furrer Daniela, et al.
Published: (2013)

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
by: Lu-Qi Cao, et al.
Published: (2024)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
by: Alexander Rau, et al.
Published: (2021)

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
by: Chia-Hsien Shih, et al.
Published: (2024)

Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody-Drug Conjugate Therapies
by: Molly Major, et al.
Published: (2024)

Expression of HER2/neu in gastric adenocarcinoma and its correlation with serum HER2/neu level and E-cadherin expression
by: Ishan Pandey, et al.
Published: (2022)

Peptidomimetic-based antibody surrogate for HER2
by: Mengmeng Zheng, et al.
Published: (2021)

Expression of Her-2/neu in extrahepatic cholangiocarcinoma
by: Shamekh R, et al.
Published: (2017)

Laura Middleton; Her Brother and her Lover
by: Anonymous